Kamada Ltd.

KMDA Healthcare Drug Manufacturers Specialty & Generic

Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024.

Revenue
+22.7%
EPS
+23.1%
Free cash flow
+165.7%
Total debt
−38.8%

Quarter to June 2026, against a year earlier

7.22 0.35 +5.09%
Market cap
$396.3M
P/E
19.0×
Fwd P/E
0.0×
Dividend yield
5.82%
F-score
7/9
Altman Z
3.33
Beneish M
−2.35
Dividend safety
50/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
8.40% 7.97% 7.64% 7.86%

+8 more TTM periods

Piotroski F-Score
7 7 7 7
ROA
5.92% 5.37% 5.38% 5.61%
ROIC
8.47% 8.06% 8.06% 8.51%
Return on Tangible Assets
11.49% 11.26% 10.80% 11.17%
Average Days of Receivables
80.98 81.67 66.06 73.77
Free Cash Flow per Share
0.45 0.28 0.27 0.31
Free Cash Flow
26.32 16.36 15.65 18.34
Other line items

Show all line items

Columns are period end dates